Takeda lands anchor immunology asset in $4B TYK2 deal with Nimbus

Takeda’s $4 billion acquisition of Nimbus’ Phase III-ready TYK2 inhibitor gives the pharma a pipeline-in-a-product to jump-start an immunology franchise and take on Bristol Myers’ Sotyktu.

The deal also gives Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) an anchor immunology program to pair with its blockbuster inflammatory bowel disease therapy Entyvio vedolizumab. For Nimbus Therapeutics LLC, it is the largest exit yet from the biotech’s single-asset subsidiary model and could give long-time investors a big win...